Silo Pharma Inc.

Silo Pharma Inc.

507 views1 min read

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Silo Pharma
Englewood Cliffs NJ, Oct. 07, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with ... Read More...
1354 views2 min read

Silo Pharma Advances Psychedelic Patent Portfolio

Silo Pharma
Englewood Cliffs NJ, Aug. 25, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflamma... Read More...
Joint VentureM & A800 views1 min read

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

Silo Pharma
Englewood Cliffs NJ, Aug. 11, 2021 -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Departmen... Read More...
1394 views1 min read

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Silo Pharma
Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notic... Read More...
99 views2 min read

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

Silo Pharma
Englewood Cliffs NJ, July 12, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a development stage biopharmaceutical company, today announced that it has entered into a Scientific Research Agreement with the University of Maryland, Baltimore.  The main objective of our study is to evaluate the pharmacokinetics of dexamethasone delivered to arthri... Read More...
58 views1 min read

Silo Pharma Submits Application for NASDAQ up-listing

Silo Pharma
Englewood Cliffs, NJ, May 25, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (“NASDAQ”).The Company previously announced its board approval to... Read More...
28 views2 min read

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Silo Pharma
Englewood Cliffs, NJ, June 08, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four ... Read More...
141 views2 min read

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma
Silo Pharma could Utilize Data for Psilocybin Delivery potential to Central Nervous SystemEnglewood Cliffs, NJ, Jan. 13, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PT... Read More...
375 views2 min read

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo Pharma
Englewood Cliffs, NJ, Jan. 11, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million.  The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a li... Read More...
109 views1 min read

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma
Englewood Cliffs, NJ, Jan. 06, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent ... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!